Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

10.6K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
10.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Data Quality in Clinical Trials: Cross-Company Validation of the Open-Source Clinical Trial Anomaly Spotter (CTAS).

Therapeutic innovation & regulatory science·2026
Same author

VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth <i>in vitro</i>.

Oncoscience·2021
Same author

Ten simple rules for measuring the impact of workshops.

PLoS computational biology·2018
Same author

Further pharmacological characterization of eltoprazine: focus on its anxiolytic, anorexic, and adverse‑effect potential.

Acta neurobiologiae experimentalis·2017
Same author

Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain.

Pharmacological reports : PR·2016
Same author

Chemical databases: curation or integration by user-defined equivalence?

Drug discovery today. Technologies·2015
Same journal

Correction to "AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus".

Journal of chemical information and modeling·2026
Same journal

MolPy: A Large Language Model-Friendly Toolkit for Reactive Topology Editing in Polymer Simulations.

Journal of chemical information and modeling·2026
Same journal

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
Same journal

Structural and Thermodynamic Discrimination between Agonists and Antagonists of Retinoic Acid Receptor γ and the Vitamin D Receptor.

Journal of chemical information and modeling·2026
Same journal

PACEff Builder: An Efficient Platform for Constructing PACE Hybrid-Resolution Models for Molecular Dynamics Simulations of Aqueous Protein, Peptide Assembly, and Membrane Protein Systems.

Journal of chemical information and modeling·2026
Same journal

TransKla: A Local-Global Cross-Attention Based Transformer Approach for Prediction of Lysine Lactylation Sites.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Estimating error rates in bioactivity databases.

Pekka Tiikkainen1, Louisa Bellis, Yvonne Light

  • 1Merz Pharmaceuticals GmbH , Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany.

Journal of Chemical Information and Modeling
|October 29, 2013
PubMed
Summary
This summary is machine-generated.

This study quantifies errors in bioactivity databases (ChEMBL, Liceptor, WOMBAT), finding small molecule structures most error-prone. Understanding these data errors is crucial for accurate drug discovery decisions.

More Related Videos

A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

70.1K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

331

Related Experiment Videos

Last Updated: May 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

70.1K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

331

Area of Science:

  • Drug Discovery
  • cheminformatics
  • Bioactivity Data Analysis

Background:

  • Bioactivity databases are essential for drug discovery, aiding target prediction for small molecules.
  • Manual curation from scientific literature and patents introduces human errors, potentially leading to flawed early-stage drug discovery decisions.

Purpose of the Study:

  • To compare bioactivity data from ChEMBL, Liceptor, and WOMBAT databases using identical source documents.
  • To estimate error rates for various data parameters and identify databases with higher error frequencies.
  • To highlight the impact of data quality on drug discovery and guide data curation efforts.

Main Methods:

  • Comparative analysis of curated bioactivity data from three major databases (ChEMBL, Liceptor, WOMBAT).
  • Estimation of error rates for specific parameters including small molecule structures, target information, activity values, and activity types.
  • Analysis of supplier-specific error rates to identify potential curation inconsistencies.

Main Results:

  • Small molecule structures exhibit the highest estimated error rate, followed by target, activity value, and activity type.
  • Error rate patterns are consistent across supplier-specific estimates.
  • Identified specific data points and parameter types that are most susceptible to errors, aiding in targeted data re-curation.

Conclusions:

  • The study provides crucial error rate estimates for key bioactivity data parameters across major databases.
  • Awareness of error frequencies and types in bioactivity data is vital for scientists to mitigate risks in drug discovery.
  • The findings support the need for improved data curation standards and targeted re-curation efforts to enhance data reliability.